BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26483203)

  • 1. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.
    Sun W; Xie Z; Liu Y; Zhao D; Wu Z; Zhang D; Lv H; Tang S; Jin N; Jiang H; Tan M; Ding J; Luo C; Li J; Huang M; Geng M
    Cancer Res; 2015 Nov; 75(22):4923-36. PubMed ID: 26483203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors.
    Liu Y; Xie Z; Zhao D; Zhu J; Mao F; Tang S; Xu H; Luo C; Geng M; Huang M; Li J
    J Med Chem; 2017 Mar; 60(6):2227-2244. PubMed ID: 28230989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells.
    Kawano Y; Sasano T; Arima Y; Kushima S; Tsujita K; Matsuoka M; Hata H
    Biochem Biophys Res Commun; 2022 Jan; 587():153-159. PubMed ID: 34875534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.
    Zhang W; Hu X; Chakravarty H; Yang Z; Tam KY
    ACS Comb Sci; 2018 Nov; 20(11):660-671. PubMed ID: 30350563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cancer Metabolism Plasticity with JX06 Nanoparticles via Inhibiting PDK1 Combined with Metformin for Endometrial Cancer Patients with Diabetes.
    Yang X; Cheng Y; Zhou J; Zhang L; Li X; Wang Z; Yin S; Zhai L; Huang T; Wu X; Shen B; Dong Y; Zhao L; Chi Y; Jia Y; Wang J; He Y; Dong X; Xiao H; Wang J
    Adv Sci (Weinh); 2022 Mar; 9(8):e2104472. PubMed ID: 35064767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
    Zhang W; Zhang SL; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells.
    Zhang SL; Zhang W; Yang Z; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():87-92. PubMed ID: 28347773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
    Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.
    Zhang SL; Yang Z; Hu X; Tam KY
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3441-3445. PubMed ID: 30266541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
    Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
    Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
    Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
    Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
    Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
    Medina JR
    J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    Zhang W; Su J; Xu H; Yu S; Liu Y; Zhang Y; Sun L; Yue Y; Zhou X
    PLoS One; 2017; 12(6):e0179672. PubMed ID: 28617852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.
    Busschots K; Lopez-Garcia LA; Lammi C; Stroba A; Zeuzem S; Piiper A; Alzari PM; Neimanis S; Arencibia JM; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2012 Sep; 19(9):1152-63. PubMed ID: 22999883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin Therapy Results in Mitigation of ATP Loss after Irradiation Combined with Wound Trauma: Preservation of Pyruvate Dehydrogenase and Inhibition of Pyruvate Dehydrogenase Kinase 1.
    Swift JM; Smith JT; Kiang JG
    Radiat Res; 2015 Jun; 183(6):684-92. PubMed ID: 26010714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
    Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
    J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics.
    Chu F; Koomen JM; Kobayashi R; O'Brian CA
    Cancer Res; 2005 Nov; 65(22):10478-85. PubMed ID: 16288040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. For a PDK1 inhibitor, the substrate matters.
    Knight ZA
    Biochem J; 2011 Jan; 433(2):e1-2. PubMed ID: 21175429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.